"The U.S. Food and Drug Administration today notified Ranbaxy Laboratories, Ltd., that it is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility in Toansa, India, for FDA-regulated drug product"...
(Generic versions may still be available.)
Manifestations: Clinical experience with pentazocine overdosage has been insufficient to define the signs of this condition. Signs of salicylate overdosage include headache, dizziness, confusion, tinnitus, diaphoresis, thirst, nausea, vomiting, diarrhea, tachycardia, tachypnea, Kussmaul breathing, convulsions, and coma. Death is usually from respiratory failure.
Treatment: Treatment for overdosage of TALWIN Compound (pentazocine and aspirin) , should include treatment for salicylate poisoning as outlined in standard references.
Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Assisted or controlled ventilation should also be considered. For respiratory depression due to overdosage or unusual sensitivity to pentazocine, parenteral naloxone is a specific and effective antagonist.
TALWIN Compound (pentazocine and aspirin) should not be administered to patients who are hypersensitive to either pentazocine or salicylates, or in any situation where aspirin is contraindicated.
Last reviewed on RxList: 1/28/2005
This monograph has been modified to include the generic and brand name in many instances.
Additional Talwin Compound Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.